Literature DB >> 27528

Effects of acidified fetal bovine serum on the fibrinolytic activity and growth of cells in culture.

D J Loskutoff.   

Abstract

The fibrinolytic activity of cells in culture varied with the type of serum employed in the growth medium. Degradation of iodinated fibrin occurred slowly when Rous sarcoma virus-transformed chick embryo fibroblasts were grown in medium containing fetal bovine serum (FBS), and rapidly when chicken serum was employed. This difference reflected the low plasminogen and high inhibitor content of FBS. The inhibitors were found to be serum macromolecules that were precipitated with ammonium sulfate or polyethylene glycol, and were inactivated by boiling or upon exposure to acidic conditions. No inhibitor activity was detected in fetuin, one of the major proteins present in FBS. Acidified FBS was similar to chicken serum in that both supported high rates of cell-mediated fibrinolytic activity. Although virally transformed hamster, mouse and chicken cells grew well in acid-treated FBS, their normal counterparts did not. Apparently, acifification resulted in the formation of materials that were toxic to normal cells. These agents rapidly blocked cellular DNA synthesis.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 27528     DOI: 10.1002/jcp.1040960312

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  10 in total

1.  Production of plasminogen activator in cultures of superior cervical ganglia and isolated Schwann cells.

Authors:  A Alvarez-Buylla; J E Valinsky
Journal:  Proc Natl Acad Sci U S A       Date:  1985-05       Impact factor: 11.205

2.  Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells.

Authors:  D J Loskutoff; J A van Mourik; L A Erickson; D Lawrence
Journal:  Proc Natl Acad Sci U S A       Date:  1983-05       Impact factor: 11.205

3.  A high-affinity receptor for urokinase plasminogen activator on human keratinocytes: characterization and potential modulation during migration.

Authors:  H McNeill; P J Jensen
Journal:  Cell Regul       Date:  1990-10

4.  A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase.

Authors:  J D Vassalli; D Baccino; D Belin
Journal:  J Cell Biol       Date:  1985-01       Impact factor: 10.539

5.  The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes.

Authors:  A Estreicher; J Mühlhauser; J L Carpentier; L Orci; J D Vassalli
Journal:  J Cell Biol       Date:  1990-08       Impact factor: 10.539

6.  Tumor promoter PMA stimulates the synthesis and secretion of mouse pro-urokinase in MSV-transformed 3T3 cells: this is mediated by an increase in urokinase mRNA content.

Authors:  D Belin; F Godeau; J D Vassalli
Journal:  EMBO J       Date:  1984-08       Impact factor: 11.598

7.  Urokinase-type plasminogen activator is induced in migrating capillary endothelial cells.

Authors:  M S Pepper; J D Vassalli; R Montesano; L Orci
Journal:  J Cell Biol       Date:  1987-12       Impact factor: 10.539

8.  The extracellular matrix of normal chick embryo fibroblasts: its effect on transformed chick fibroblasts and its proteolytic degradation by the transformants.

Authors:  S Fairbairn; R Gilbert; G Ojakian; R Schwimmer; J P Quigley
Journal:  J Cell Biol       Date:  1985-11       Impact factor: 10.539

9.  Reciprocal modulation of surface expression of annexin A2 in a human umbilical vein endothelial cell-derived cell line by eicosapentaenoic acid and docosahexaenoic acid.

Authors:  Jungha Park; Takayuki Yamaura; Jun Kawamoto; Tatsuo Kurihara; Satoshi B Sato
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

10.  S100A10, a novel biomarker in pancreatic ductal adenocarcinoma.

Authors:  Moamen Bydoun; Andra Sterea; Henry Liptay; Andrea Uzans; Weei-Yuarn Huang; Gloria J Rodrigues; Ian C G Weaver; Hong Gu; David M Waisman
Journal:  Mol Oncol       Date:  2018-09-21       Impact factor: 6.603

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.